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Background. Left ventricular diastolic dysfunction has been
shown in patients with autosomal-dominant polycystic kidney
disease (ADPKD). However, there is no study evaluating right
ventricular functions in these patients.
Methods. In the present study, diastolic functions of both
ventricles in normotensive and hypertensive ADPKD patients
with well-preserved renal function were investigated. Fifteen
hypertensive and 16 normotensive patients with ADPKD with
well-preserved renal function, 16 patients with essential hyper-
tension, and 24 healthy subjects were included in the study.
Conventional left and right ventricular echocardiographic
measurements were performed in all subjects. Left and right
ventricular functions were investigated both by myocardial per-
formance index (MPI) [calculated by dividing the sum of isovo-
lumic contraction time and isovolumic relaxation time (IVRT)
by ejection time] and by tissue Doppler imaging (TDI).
Results. Left ventricular deceleration time and IVRT were
significantly prolonged in hypertensive patients with ADPKD
compared with patients with essential hypertension and even
in normotensive patients with ADPKD compared with healthy
subjects. Left and right MPIs were significantly higher in pa-
tients with ADPKD compared with healthy subjects, showing
systolic and diastolic dysfunction. Moreover, by using TDI, the
peak early diastolic mitral annular velocity (Em) to peak late
diastolic mitral annular velocity (Am) ratio and the peak early
diastolic tricuspid annular velocity (Et) to peak late diastolic
tricuspid annular velocity (At) ratio were decreased in patients
with ADPKD, suggesting biventricular diastolic dysfunction.
Conclusion. Both hypertensive and normotensive patients
with ADPKD show significant biventricular diastolic dysfunc-
tion, suggesting cardiac involvement very early in the course of
ADPKD.
Autosomal-dominant polycystic kidney disease
(ADPKD) is the most common hereditary renal disease,
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accounting for approximately 4% of end-stage renal
disease (ESRD) in the United States and 8% to 10% in
Europe [1]. Cardiovascular problems are a major cause
of morbidity and mortality in patients with ADPKD
[2, 3]. Hypertension and left ventricular hypertrophy
(LVH), which are common findings in ADPKD, are
associated with a faster progression to ESRD and an
increased cardiovascular mortality [2–5]. Importantly,
several studies have shown increased left ventricular
mass (LVM) indexes, left ventricular (LV) diastolic
dysfunction, endothelial dysfunction, increased carotid
intima-media thickness, and exaggerated blood pressure
response during exercise even in young normotensive
patients with ADPKD with well-preserved renal func-
tion [4, 6–11]. These findings suggest that cardiovascular
involvement starts very early in the course of ADPKD.
However, there is no study evaluating right ventricular
(RV) functions in these patients.
The aim of the present study was to investigate dias-
tolic functions of both ventricles in normotensive and hy-
pertensive ADPKD patients with well-preserved renal
function.
METHODS
Patients
Thirty-one patients with ADPKD were included in the
study. Fifteen of these patients had hypertension (blood
pressure ≥140/90 mm Hg in the sitting position or taking
antihypertensive drugs) and 16 were normotensive. Six-
teen patients with essential hypertension and 24 healthy
subjects were also included in the study.
The diagnosis of ADPKD was reached by the ultra-
sonographic criteria described by Ravine et al [12]. All of
the patients had family history of ADPKD.
Creatinine clearances were calculated by the Cock-
croft-Gault formula [13]. All patients had creatinine
clearances greater than 60 mL/min/1.73m2.
The study protocol was approved by the institutional
medical ethics committee and written informed consent
was obtained from all subjects included in the study.
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Table 1. Characteristics of patients
Hypertensive Normotensive Patients with
patients with patients with essential hypertension Healthy subjects
ADPKD (N = 15) ADPKD (N = 16) (N = 16) (N = 24)
Age years 39.6 ± 7.2 35.8 ± 8.8 40.8 ± 4.8 38.1 ± 8.8
Gender M/F 4/11 7/9 7/9 8/16
Body mass index kg/m2 25.5 ± 3.5 23.7 ± 3.8 26.0 ± 3.2 24.7 ± 3.5
Systolic blood pressure mm Hg 138 ± 18a 120 ± 18 134 ± 14a 119 ± 14
Diastolic blood pressure mm Hg 85 ± 11a 74 ± 8 77 ± 13 75 ± 9
Age of diagnosis of hypertension years 37.3 ± 19.5 – 42.3 ± 17.5 –
Duration of hypertension months 56.3 ± 52.3 – 41.9 ± 48.4 –
Creatinine clearance mL/min/1.73m2 91 ± 29 106 ± 17 112 ± 14 105 ± 12
aP < 0.01 vs. normotensive patients with ADPKD and healthy subjects.
Systolic and diastolic blood pressures were measured
on the right arm of the subjects in an upright sitting posi-
tion after at least 5 minutes of rest using an Erka sphyg-
momanometer (PMS Instruments, Ltd., Berkshire, UK)
with appropriate cuff size. Two readings were recorded
for each individual. The average of two readings was de-
fined as the subject’s blood pressure.
All of the patients had grade 1 functional capacity ac-
cording to New York Heart Association classification.
None of the patients had history, physical findings, and
ECG findings suggesting congestive heart failure, my-
ocardial infarction, and chronic obstructive pulmonary
disease.
Venous blood samples for the biochemical analyses
were taken after an overnight fast between 8 PM and
8 AM.
Echocardiographic examination
Echocardiographic examination was performed us-
ing a Vingmed System Five, Norway echocardiographic
system equipped with 2.5-MHz transducers (Vingmed
Sound, Norway). M-Mode and two-dimensional mea-
surements were performed in accordance with methods
recommended by the American Society of Echocardiog-
raphy [14, 15]. Cardiac mass was calculated by means of
the formula derived by Devereux and Reichek [16]. LVH
was defined as left ventricular mass index (LVMI) >125
g/m2 for males and >110 g/m2 for females. The intraob-
server and interobserver coefficients of variability for LV
mass indexes were 4.1% and 7.1%, respectively.
Conventional left and right ventricular echocardio-
graphic measurements were performed in all subjects.
Measurements included LV deceleration time (LV DT),
LV isovolumic relaxation time (LV IVRT), LV early to
atrial peak velocity ratio (E/A ratio), RV E/A ratio. Left
ventricular ejection fraction (LV EF) was measured by
using the Teichholtz formula [17].
Left and right ventricular functions were also inves-
tigated by using myocardial performance index (MPI).
MPI was calculated by the formula: MPI = (isovolumic
contraction time + isovolumic relaxation time)/ejection
time) [18].
Pulsed wave tissue Doppler imaging (TDI) was per-
formed by activating the TDI function of the same ma-
chine. The spectral pulsed Doppler signal was arranged
to obtain a Nyquist limit of 15 to 20 cm/s with the lowest
wall filter settings. From the apical four-chamber view, a
5 mm sample volume was located at the ventricle free
wall near to the lateral tricuspid and the posterior mitral
leaflets. The resulting velocities were recorded for five cy-
cles at a sweep speed of 50 mm/s and stored on videotape
for later analysis. The following parameters were deter-
mined: peak systolic mitral annular velocity (Sm), peak
early diastolic mitral annular velocity (Em), peak late di-
astolic mitral annular velocity (Am), mitral Em/Am ratio,
peak systolic tricuspid annular velocity (St), peak early
diastolic tricuspid annular velocity (Et), peak late dias-
tolic tricuspid annular velocity (At), and tricuspid Et/At
ratio.
The Doppler imaging calculations of both left and right
ventricles were performed during the end of the expir-
ium. Pulmonary artery pressures were calculated by the
modified Bernoulli equation in patients with tricuspid re-
gurgitation [19]. Since only 30% to 40% of the subjects in
all groups had tricuspid regurgitation, pulmonary artery
pressures were not determined in all of the subjects. The
calculated pulmonary artery pressures were within nor-
mal limits (<30 mm Hg).
Statistical analyses
Comparison of groups was performed using Mann-
Whitney U and chi-square tests. Mann-Whitney U test
was applied to the groups in pairs, for all possible combi-
nations. P less than 0.05 was considered statistically sig-
nificant. All values are expressed as mean ± SD.
RESULTS
There was no significant difference between the groups
regarding age, gender, body mass index, and renal
function (Table 1). Hypertensive ADPKD patients and
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Table 2. Conventional echocardiographic measurements
Hypertensive Normotensive Patients with
patients with patients with essential hypertension Healthy subjects
ADPKD (N = 15) ADPKD (N = 16) (N = 16) (N = 24)
LVMI g/m2 132 ± 23a 108 ± 24 111 ± 16b 95 ± 17
LV EF% 68 ± 12 71 ± 14 70 ± 14 73 ± 14
LV DT msec 188 ± 37c 172 ± 44d 158 ± 21d 141 ± 15
LV IVRT msec 132 ± 17e 115 ± 19d 117 ± 14d 95 ± 9
LV E/A 0.91 ± 0.22e 1.31 ± 0.29f 1.09 ± 0.17d 1.49 ± 0.21
RV E/A 1.25 ± 032 1.33 ± 0.29 1.23 ± 0.23 1.31 ± 0.16
LA-D mm 31 ± 7 29 ± 7 30 ± 8 28 ± 6
RA-D mm 29 ± 4 27 ± 4 30 ± 3 27 ± 4
RV-D mm 23 ± 4 21 ± 3 22 ± 5 20 ± 3
Abbreviations are: LV MI, left ventricular mass index; LV EF, left ventricular ejection fraction; LV DT, left ventricular deceleration time; LV IVRT, left ventricular
isovolumic relaxation time; LV E/A, left ventricular early to atrial peak velocity ratio; RV E/A, right ventricular early to atrial peak velocity ratio; LA-D, left atrium
diameter; RA-D, right atrium diameter; RV-D, right ventricular diameter.
aP = 0.02 vs. normotensive patients with ADPKD, P < 0.02 vs. patients with essential hypertension, P < 0.0001 vs. healthy subjects.
bP = 0.005 vs. healthy subjects.
cP = 0.01 vs. patients with essential hypertension, P < 0.001 vs. healthy subjects.
dP < 0.05 vs. healthy subjects.
eP < 0.05 vs. normotensive patients with ADPKD and patients with essential hypertension, P < 0.001 vs. healthy subjects.
fP < 0.05 vs. healthy subjects.
essential hypertensive patients had significantly higher
systolic blood pressures compared to normotensive
ADPKD patients and healthy subjects. Hypertensive
ADPKD patients also had significantly higher diastolic
blood pressure compared to normotensive ADPKD pa-
tients and healthy subjects.
The patients continued to receive their antihyperten-
sive medications during the study. Five patients were
administered angiotensin-converting enzyme (ACE) in-
hibitors; 4 patients, calcium channel blockers (CCBs);
3 patients, angiotensin-receptor blockers (ARBs); 3 pa-
tients, a combination of ACE inhibitors and CCBs in the
hypertensive ADPKD group. Six patients were adminis-
tered ACE inhibitors; 3 patients, CCBs; 4 patients, ARBs;
3 patients, a combination of ACE inhibitors and CCBs;
and 1 patient, a beta-blocker in the essential hyperten-
sive group. No statistically significant difference in anti-
hypertensive use was present between the hypertensive
ADPKD group and essential hypertensive group.
Hypertensive ADPKD patients had significantly
higher LVMI compared to all other groups. Patients
with essential hypertension also had significantly ele-
vated LVMI compared to healthy subjects. Normotensive
ADPKD patients had higher LVMI compared to healthy
subjects. Although this was not statistically significant, the
P value was 0.06 (Table 2). LVH was present in 12 (80%)
of the hypertensive patients with ADPKD, 6 (38%) of the
normotensive patients with ADPKD, and 8 (50%) of the
patients with essential hypertension. None of the healthy
subjects had LVH.
Left ventricular EFs were similar and within normal
limits in all groups. Left ventricular DT was significantly
prolonged in hypertensive patients with ADPKD com-
pared with patients with essential hypertension (188 ±
37 msec vs. 158 ± 21 msec, P = 0.01) and healthy sub-
jects (188 ± 37 msec vs. 141 ± 15 msec, P < 0.001). Left
ventricular DT was significantly longer even in normoten-
sive patients with ADPKD than healthy subjects (172 ±
44 msec vs. 141 ± 15 msec, P < 0.05). Left ventricular
IVRT was significantly prolonged in hypertensive pa-
tients with ADPKD compared with normotensive pa-
tients with ADPKD (132 ± 17 msec vs. 115 ± 19 msec,
P < 0.05), patients with essential hypertension (132 ±
17 msec vs. 117 ± 14 msec, P < 0.05), and healthy sub-
jects (132 ± 17 msec vs. 95 ± 9 msec, P < 0.001). Left
ventricular IVRT was significantly longer even in nor-
motensive patients with ADPKD than healthy subjects
(115 ± 19 msec vs. 95 ± 9 msec, P < 0.05) (Table 2).
Left ventricular E/A ratio was significantly decreased
in hypertensive patients with ADPKD compared with
normotensive patients with ADPKD (0.91 ± 0.22 vs.
1.31 ± 0.29, P < 0.05), patients with essential hyperten-
sion (0.91 ± 0.22 vs. 1.09 ± 0.17, P < 0.05), and healthy
subjects (0.91 ± 0.22 vs. 1.49 ± 0.21, P < 0.001). Left
ventricular E/A ratio was significantly less in normoten-
sive patients with ADPKD than healthy subjects (1.31 ±
0.29 vs. 1.49 ± 0.21, P < 0.05). There was no signifi-
cant difference between the groups regarding RV E/A
ratios (Table 2). Left atrium diameter, right atrium, and
right ventricular diameters were within normal limits in
all groups (Table 2).
Left ventricular MPI was significantly higher in hyper-
tensive patients with ADPKD compared with normoten-
sive patients with ADPKD (0.72 ± 0.18 vs. 0.57 ± 0.18,
P < 0.05), patients with essential hypertension (0.72 ±
0.18 vs. 0.60 ± 0.12, P < 0.05), and healthy subjects (0.72 ±
0.18 vs. 0.46 ± 0.10, P < 0.001). Moreover, LV MPI was
significantly higher even in normotensive patients with
ADPKD than healthy subjects (0.57 ± 0.18 vs. 0.46 ±
0.10, P < 0.05) (Fig. 1).
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Fig. 1. Left ventricular myocardial performance index. ∗P < 0.05 vs.
normotensive patients with ADPKD and patients with essential hyper-
tension, P < 0.001 vs. healthy subjects; ∗∗P < 0.05 vs. healthy subjects.
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Fig. 2. Right ventricular myocardial performance index. ∗ P < 0.05 vs.
healthy subjects.
Right ventricular MPI was significantly higher in hy-
pertensive patients with ADPKD compared with healthy
subjects (0.52 ± 0.12 vs. 0.37 ± 0.10, P < 0.05). Right ven-
tricular MPI was significantly higher even in normoten-
sive patients with ADPKD than healthy subjects (0.48 ±
0.14 vs. 0.37 ± 0.10, P < 0.05) (Fig. 2).
The subjects were also investigated by using TDI. The
peak systolic mitral annular velocity (Sm) and the peak
systolic tricuspid annular velocity (St), reflecting left and
right ventricular systolic functions, were similar in all
groups. However, Em/Am ratio, showing left ventricular
diastolic function, was significantly decreased in hyper-
tensive patients with ADPKD compared with normoten-
sive patients with ADPKD (1.01 ± 0.43 vs. 1.34 ± 0.37,
P = 0.03) and healthy subjects (1.01 ± 0.43 vs. 1.38 ±
0.19, P = 0.001). Similarly, Et/At ratio, showing right ven-
tricular diastolic function, was significantly decreased in
hypertensive patients with ADPKD compared with nor-
motensive patients with ADPKD (0.93 ± 0.27 vs. 1.23 ±
0.29, P = 0.008) and healthy subjects (0.93 ± 0.27 vs.
1.42 ± 0.14, P < 0.0001). Moreover, Et/At ratio was sig-
nificantly decreased even in normotensive patients with
ADPKD compared with healthy subjects (1.23 ± 0.29 vs.
1.42 ± 0.14, P = 0.02) (Table 3).
DISCUSSION
Hypertension and LVH, which are powerful indepen-
dent risk factors for cardiovascular morbidity and mor-
tality, occur frequently in patients with ADPKD [2–4, 20].
Hypertension develops early in 50% to 70% of patients
with ADPKD before any substantial decrease in kid-
ney function [2, 21]. Activation of the renin-angiotensin-
aldosterone system (RAAS) due to cyst expansion and
local renal ischemia has been proposed to play an impor-
tant role in the development of hypertension in ADPKD
[2, 22]. The RAAS is activated at an early stage of
ADPKD, even before the onset of hypertension and clin-
ical findings [23, 24]. Since the RAAS plays a detrimental
role in the pathogenesis of target organ damage, such as
atherosclerosis, LVH, heart failure, and ESRD [25–28],
the increased activity of the RAAS may contribute to
the increased incidence of cardiovascular complications
in patients with ADPKD.
In the present study, hypertensive patients with
ADPKD had significantly higher LVMI compared to
the subjects in all other groups. The high incidence of
LVH has been reported in patients with ADPKD [4]. Im-
portantly, a high prevalence of LVH has been reported
even in normotensive patients with ADPKD compared
to healthy control subjects [4, 6, 7]. In our study, nor-
motensive ADPKD patients had higher LVMI compared
to healthy subjects. Although this was not statistically sig-
nificant, the P value was 0.06.
It has been reported that there is an association be-
tween insulin resistance and LVH [29, 30]. Lumiaho et
al [31] reported that insulin resistance was significantly
associated with LVMI in healthy relatives and patients
with mutations in the PKD1 gene independently of other
factors known to increase LVMI, such as age, weight, sys-
tolic blood pressure, and albuminuria. It can thus be hy-
pothesized that the stimulation of angiotensin II and the
sympathetic nervous system due to hyperinsulinemia may
contribute to increased LVMI in these patients [32, 33].
In the present study, LV systolic functions were found
to be within normal limits in all groups of patients, while
LV diastolic functions were significantly impaired both in
hypertensive and normotensive patients with ADPKD
compared to healthy subjects. Left ventricular diastolic
dysfunction was previously reported in young normoten-
sive patients with ADPKD [7]. In our study, diastolic
functions of both ventricles were investigated in patients
with ADPKD with well-preserved renal function.
A limitation of the study was that the number of sub-
jects in each group was relatively small. Thus, although
there was no statistically significant difference between
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Table 3. Tissue Doppler imaging measurements
Hypertensive Normotensive Patients with
patients with patients with essential hypertension Healthy subjects
ADPKD (N = 15) ADPKD (N = 16) (N = 16) (N = 24)
Sm cm/sec 9.0 ± 2.2 9.3 ± 1.8 8.6 ± 1.6 9.4 ± 1.6
Em/Am 1.01 ± 0.43a 1.34 ± 0.37b 1.03 ± 0.18c 1.38 ± 0.19
St cm/sec 15.3 ± 2.2 15.3 ± 2.3 13.9 ± 1.7 15.1 ± 2.3
Et/At 0.93 ± 0.27d 1.23 ± 0.29e 0.96 ± 0.29c 1.42 ± 0.14
Abbreviations are: Sm, peak systolic mitral annular velocity; Em, peak early diastolic mitral annular velocity; Am, peak late diastolic mitral annular velocity; St, peak
systolic tricuspid annular velocity; Et, peak early diastolic tricuspid annular velocity; At, peak late diastolic tricuspid annular velocity.
aP = 0.03 vs. normotensive patients with ADPKD, P = 0.001 vs. healthy subjects.
bP = 0.006 vs. patients with essential hypertension.
cP < 0.0001 vs. healthy subjects.
dP = 0.008 vs. normotensive patients with ADPKD, P < 0.0001 vs. healthy subjects.
eP = 0.02 vs. patients with essential hypertension and healthy subjects.
the frequency of antihypertensive medication use, the ef-
fects of these drugs on our findings cannot be neglected.
In this study, in addition to the conventional echocar-
diographic measurements, left and right ventricular func-
tions were also investigated by using MPI. Myocardial
performance index, which was first described by Tei [18],
is a simple and reproducible method used for the assess-
ment of overall cardiac function [34–37]. It is defined as
the ratio of total time spent in isovolumic activity (isovo-
lumic contraction time and isovolumic relaxation time) to
the ejection time. The increased rate of MPI in patients
with ADPKD suggests diastolic dysfunction.
Interpretation of right ventricular functions is a chal-
lenging problem because of the complex and asymmet-
ric architecture of the right ventricle. Three-dimensional
echocardiography or magnetic resonance imaging can be
used for the evaluation of right ventricle [38, 39]. Tissue
Doppler imaging is a new technique that analyzes sys-
tolic and diastolic functions of both ventricles accurately.
Annular velocities, determined by TDI, are reported to
be independent from preload compensation [40]. In the
present study, while the values of peak systolic tricuspid
annular velocity (St) were similar in all groups, both hy-
pertensive and normotensive patients with ADPKD had
significantly lower Em/Am and Et/At ratios, showing left
ventricular and right ventricular diastolic dysfunctions,
respectively.
This is the first study investigating systolic and diastolic
dysfunction of both ventricles in patients with ADPKD.
CONCLUSION
Both hypertensive and normotensive patients with
ADPKD show significant biventricular diastolic dysfunc-
tion. The clinical significance of this finding needs to be
determined in further studies.
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